These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23053472)

  • 1. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients.
    Baruteau J; Sachs P; Broué P; Brivet M; Abdoul H; Vianey-Saban C; Ogier de Baulny H
    J Inherit Metab Dis; 2013 Sep; 36(5):795-803. PubMed ID: 23053472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive test using palmitate in patients with suspected fatty acid oxidation defects: disease-specific acylcarnitine patterns can help to establish the diagnosis.
    Janzen N; Hofmann AD; Schmidt G; Das AM; Illsinger S
    Orphanet J Rare Dis; 2017 Dec; 12(1):187. PubMed ID: 29268767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
    Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
    Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study from 187 patients. Complementary data.
    Baruteau J; Sachs P; Broué P; Brivet M; Abdoul H; Vianey-Saban C; Ogier de Baulny H
    J Inherit Metab Dis; 2014 Jan; 37(1):137-9. PubMed ID: 23807318
    [No Abstract]   [Full Text] [Related]  

  • 5. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
    Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
    Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiologic evaluation of Turkish mitochondrial fatty acid oxidation disorders.
    Balci MC; Karaca M; Ergul Y; Omeroglu RE; Demirkol M; Gokcay GF
    Pediatr Int; 2022 Jan; 64(1):e15317. PubMed ID: 36331231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening.
    Yusupov R; Finegold DN; Naylor EW; Sahai I; Waisbren S; Levy HL
    Mol Genet Metab; 2010 Sep; 101(1):33-9. PubMed ID: 20580581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
    Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
    BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, genetic characterization and clinical follow up of mitochondrial fatty acid oxidation disorders in the new era of expanded newborn screening: A single centre experience.
    Maguolo A; Rodella G; Dianin A; Nurti R; Monge I; Rigotti E; Cantalupo G; Salviati L; Tucci S; Pellegrini F; Molinaro G; Lupi F; Tonin P; Pasini A; Campostrini N; Ion Popa F; Teofoli F; Vincenzi M; Camilot M; Piacentini G; Bordugo A
    Mol Genet Metab Rep; 2020 Sep; 24():100632. PubMed ID: 32793418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Screening of Fatty Acids Oxidation Defects and Organic Acidemias by Liquid Chromatography/tandem Mass Spectrometry Acylcarnitine Analysis in Brazilian Patients.
    Vargas CR; Ribas GS; da Silva JM; Sitta A; Deon M; de Moura Coelho D; Wajner M
    Arch Med Res; 2018 Apr; 49(3):205-212. PubMed ID: 30119976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
    Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Bleeker JC; Kok IL; Ferdinandusse S; de Vries M; Derks TGJ; Mulder MF; Williams M; Gozalbo ER; Bosch AM; van den Hurk DT; de Sain-van der Velden MGM; Waterham HR; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 Jan; 42(1):159-168. PubMed ID: 30740737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Newborn Screening and Early Dietary Management on Clinical Outcome of Patients with Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency and Medium Chain Acyl-CoA Dehydrogenase Deficiency-A Retrospective Nationwide Study.
    Rücklová K; Hrubá E; Pavlíková M; Hanák P; Farolfi M; Chrastina P; Vlášková H; Kousal B; Smolka V; Foltenová H; Adam T; Friedecký D; Ješina P; Zeman J; Kožich V; Honzík T
    Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of mitochondrial fatty acid oxidation defects.
    Duran M; Bruinvis L; Ketting D; Dorland L
    Padiatr Padol; 1993; 28(1):19-25. PubMed ID: 8446424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
    Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
    PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characteristics and follow-up of patients with fatty acid β-oxidation disorders through expanded newborn screening in a Northern Chinese population.
    Wang S; Leng J; Diao C; Wang Y; Zheng R
    J Pediatr Endocrinol Metab; 2020 May; 33(6):683-690. PubMed ID: 32447334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease.
    Landau YE; Waisbren SE; Chan LM; Levy HL
    J Inherit Metab Dis; 2017 Mar; 40(2):209-218. PubMed ID: 28054209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
    Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario.
    Kennedy S; Potter BK; Wilson K; Fisher L; Geraghty M; Milburn J; Chakraborty P
    BMC Pediatr; 2010 Nov; 10():82. PubMed ID: 21083904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.